Search

This case report discusses a female patient with axial spondyloarthritis (AS) who developed inflammatory bowel disease (IBD) after being treated with secukinumab (SEC), an interleukin-17 inhibitor. The patient had a family history of AS and psoriasis, and her symptoms worsened after starting SEC treatment. She experienced upper abdominal pain, nausea, vomiting, and gastrointestinal bleeding. The report highlights the association between SEC and the exacerbation of gastrointestinal symptoms leading to IBD. It also mentions the low incidence rate of IBD in patients treated with SEC and the lack of reports on neurological damage associated with SEC use. [Extracted from the article]